Cristina Aguirre-Portolés
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristina Aguirre-Portolés has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Christopher A. Natale
Linnaeus Therapeutics, Haddonfield, New Jersey
46 shared publications - John T. Seykora
Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
46 shared publications - Todd W. Ridky
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
46 shared publications - Ignacio Pérez de Castro
Institute for Rare Diseases Research, Instituto de Salud Carlos III (ISCIII) Madrid Spain
34 shared publications - Marcos Malumbres
Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
34 shared publications Marta Cañamero
32 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (3) , 65
Outcomes of elective discontinuation, retreatment, and alternatives to surgery in childhood fibrosarcoma
Outcomes of elective discontinuation, retreatment, and alternatives to surgery in childhood fibrosarcoma
- 1 March 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (3) , 65
Open AccessOutcomes of elective discontinuation, retreatment, and alternatives to surgery in childhood fibrosarcoma
Outcomes of elective discontinuation, retreatment, and alternatives to surgery in childhood fibrosarcoma
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S3. CRISPR-Cas9 depletion of GPER in human melanocytes.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S3. CRISPR-Cas9 depletion of GPER in human melanocytes.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
Off-target binding of LNS8801 and LNS8812 using Eurofins Discover X.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
Off-target binding of LNS8801 and LNS8812 using Eurofins Discover X.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
Log-rank (Mantel-Cox) all comparisions of data in Figure 2 and 4.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
Log-rank (Mantel-Cox) all comparisions of data in Figure 2 and 4.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S1. Validation of LNS8801 activity and necessity of GPER in HL-60 cells.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S1. Validation of LNS8801 activity and necessity of GPER in HL-60 cells.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S2. LNS8801 is active in the WM46 human xenograft model.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S2. LNS8801 is active in the WM46 human xenograft model.
- Open Access
- 4 April 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S3. CRISPR-Cas9 depletion of GPER in human melanocytes.
- 4 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S3. CRISPR-Cas9 depletion of GPER in human melanocytes.
- Open Access
- 4 April 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S2. LNS8801 is active in the WM46 human xenograft model.
- 4 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
S2. LNS8801 is active in the WM46 human xenograft model.
- Open Access
- 4 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
GPER is necessary, and genetic variation affects LNS8801 effects. A, Western blot demonstrating CRISPR-Cas9 GPER depletion and LNS8801 dose-response proliferation assay in YUMM1.7 cells (melanoma), n = 6 replicates per dose. B, Western blot demonstrating CRISPR-Cas9 GPER depletion and LNS8801 dose-response proliferation assay in 2838c3 cells (pancreatic cancer), n = 6 replicates per dose. C, Tumor volumes and (D) Kaplan–Meier survival curves measured over time in YUMM1.7 melanoma–bearing mice with GPER (GPER WT) and without GPER (GPER KO) treated with orally delivered vehicle or LNS8801 at 1 mg/kg, significance by log-rank (Mantel–Cox). To control for tumor size, treatment was started when tumor sizes were equal; day 7 and day 27 after tumor injection for GPER WT and GPER KO tumor-bearing mice, respectively. Additional statistical information for F is presented in Supplementary Table S2. E, CREB reporter assay of human melanocytes with CRISPR-Cas9 depleted GPER treated with LNS8801, significance by the Mann–Whitney test. F, CREB reporter assay of human melanocytes homozygous for consensus germline GPER (C/C) and heterozygous for variant germline GPER (C/V) treated with 50 nmol/L LNS8801, significance by the Mann–Whitney test.
- 4 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development
GPER is necessary, and genetic variation affects LNS8801 effects. A, Western blot demonstrating CRISPR-Cas9 GPER depletion and LNS8801 dose-response proliferation assay in YUMM1.7 cells (melanoma), n = 6 replicates per dose. B, Western blot demonstrating CRISPR-Cas9 GPER depletion and LNS8801 dose-response proliferation assay in 2838c3 cells (pancreatic cancer), n = 6 replicates per dose. C, Tumor volumes and (D) Kaplan–Meier survival curves measured over time in YUMM1.7 melanoma–bearing mice with GPER (GPER WT) and without GPER (GPER KO) treated with orally delivered vehicle or LNS8801 at 1 mg/kg, significance by log-rank (Mantel–Cox). To control for tumor size, treatment was started when tumor sizes were equal; day 7 and day 27 after tumor injection for GPER WT and GPER KO tumor-bearing mice, respectively. Additional statistical information for F is presented in Supplementary Table S2. E, CREB reporter assay of human melanocytes with CRISPR-Cas9 depleted GPER treated with LNS8801, significance by the Mann–Whitney test. F, CREB reporter assay of human melanocytes homozygous for consensus germline GPER (C/C) and heterozygous for variant germline GPER (C/V) treated with 50 nmol/L LNS8801, significance by the Mann–Whitney test.